Based on a tumor-on-a-chip platform, Bi et al. found that M1-type TAMs can inhibit angiogenesis and tumor growth by promoting the production of CXCL9, CXCL10, and CXCL11 in CRC [45]. This evidence concerns the gene CXCL10 and neoplasm.